New treatment for Helicobacter Pylori infection using tegoprazan
Efficacy of Tegoprazan-containing Sequential Therapy Compared to Proton Pump Inhibitor-based Eradication in South Korea, a Region With High Antimicrobial Resistance: A Prospective Randomized Single Tertiary Center Study
This study is testing a new 10-day treatment using tegoprazan to see if it can more effectively get rid of Helicobacter pylori infections compared to the usual treatment with esomeprazole.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Seoul National University Bundang Hospital Academic / other |
| Locations | 1 site (Seongnam-si, Gyeonggi-do) |
| Trial ID | NCT06382493 on ClinicalTrials.gov |
What this trial studies
This clinical trial evaluates the effectiveness of a 10-day sequential treatment for Helicobacter pylori infection that includes tegoprazan, a potassium-competitive acid blocker, compared to a conventional treatment that uses esomeprazole. The study is designed as a randomized controlled trial to assess the eradication rates of H. pylori in patients with confirmed infections. Given the high prevalence of antimicrobial resistance in regions like Korea, this trial aims to explore alternative antibiotic combinations to improve treatment outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with H. pylori infection confirmed by specific testing methods.
Not a fit: Patients with congestive heart failure, end-stage renal disease, or those who are pregnant or nursing will not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could provide a more effective option for eradicating H. pylori infections, particularly in patients with antibiotic resistance.
How similar studies have performed: Other studies have shown promise with potassium-competitive acid blockers in H. pylori treatment, but this specific approach is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: Patients who had H. pylori infection proved by positive test result of urea breath test (UBT), rapid urase test or pathologic examination (warthin-giemsa staining) Exclusion Criteria: * congestive heart failure, NYHA III or IV * end-stage renal disease * alcoholics * drug abusers * pregnant or nursing women
Where this trial is running
Seongnam-si, Gyeonggi-do
- Seoul National University Bundang Hospital — Seongnam-si, Gyeonggi-do, South Korea (Recruiting)
Study contacts
- Principal investigator: Nayoung Kim, Prof. — Seoul National University Bundang Hospital
- Study coordinator: Jungwon Lee, Dr.
- Email: saludos@naver.com
- Phone: 821093567758
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.